Targeting Disease at the Nuclear Pore
Karyopharm Therapeutics is an innovation-driven pharmaceutical company focused on the discovery, development, and commercialization of medicines with the goal of improving the lives of patients with cancer and other major diseases.

Phase 3 BOSTON Study results now published in The Lancet

Our Commitment to Patients

SINE Technology

Karyopharm is the industry leader in oral Selective Inhibitor of Nuclear Export (SINE) technology, developed to address a fundamental mechanism of oncogenesis.

Scientist doctor looking at sample in test tube

Pipeline

Our drug pipeline includes 4 unique investigational medicines targeting both hematologic malignancies and solid tumors.

Press Releases

December 1, 2020
Karyopharm Announces Investor and Analyst Event at the American Society of Hematology 2020 Annual Meeting
December 1, 2020
Karyopharm Expands Board of Directors and Executive Leadership Team and Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Upcoming Medical Conferences

Conference: American Society of Hematology (ASH) 2020 Annual Meeting
Location: Virtual Exhibition
Date: December 5 – 8

Targeting Disease at the Nuclear PoreKaryopharm Therapeutics is an innovation-driven pharmaceutical company focused on the discovery, development, and commercialization of medicines with the goal of improving the lives of patients with cancer and other major diseases.